908
Views
39
CrossRef citations to date
0
Altmetric
Original Research

Overcoming medication stigma in peer recovery: A new paradigm

, BA, , MHS, , MHS, , JD & , MD

References

  • Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574. doi:10.1146/annurev-publhealth-031914-122957. PMID:25581144.
  • Rudd RA. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR.Morbidity and Mortality Weekly Report. 2016;65:1445–1452. doi:10.15585/mmwr.mm655051e1.
  • Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–922. doi:10.2105/AJPH.2012.301049. PMID:23488511.
  • Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066. doi:10.1056/NEJMp1402780. PMID:24758595.
  • Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298–308. doi:10.1111/add.13193. PMID:26452239.
  • Bart G. Maintenance medication for opiate addiction: the foundation of recovery. Journal of addictive diseases. 2012;31(3):207–225. doi:10.1080/10550887.2012.694598. PMID:22873183.
  • Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–367. `doi:10.1097/ADM.0000000000000166. PMID:26406300.
  • Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93–103. doi:10.1097/ADM.0000000000000193. PMID:26808307.
  • American Society of Addiction Medicine. National practice guideline for the use of medications in the treatment of addiction involving opioid use. 2015. https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf. Accessed November 28, 2016.
  • Han B, Hedden S, Lipari R, Copello E, Kroutil L. Receipt of Services for Behavioral Health Problems: Results From the 2014 National Survey on Drug Use and Health. xx, xx: Substance Abuse and Mental Health Services Administration; 2015. https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-FRR3-2014/NSDUH-DR-FRR3-2014/NSDUH-DR-FRR3-2014.pdf. Accessed December 1, 2016.
  • Peyrot M. Narcotics anonymous: its history, structure, and approach. Int J Addict. 1985;20(10):1509–1522. doi:10.3109/10826088509047242. PMID:3912337.
  • Galanter M, Seppala M, Klein A. Medication-assisted treatment for opioid dependence in twelve-step-oriented residential rehabilitation settings. Substance abuse. 2016;37(3):381–383
  • Andraka-Christou B. Social & Legal Perspectives on Underuse of Medication-Assisted Treatment for Opioid Dependence. Indiana University; 2016.
  • NA World Services. NA groups & medication. Item No 2205. Chatsworth, CA. https://www.na.org/admin/include/spaw2/uploads/pdf/servicemat/Dec2011_NA_Groups_and_Medication.pdf. Published 2007. Accessed November, 5, 2016.
  • White WL. Narcotics Anonymous and the Pharmacotherapeutic Treatment of Opioid Addiction in the United States. Chicago, IL: Philadelphia Department of Behavioral Health and Intellectual Disability Services and Great Lakes Addiction Technology Transfer Center; 2011. http://atforum.com/documents/2011NAandMedication-assistedTreatment.pdf. Accessed Nov 28, 2016.
  • Allen B, Harocopos A. Non-prescribed buprenorphine in New York City: motivations for use, practices of diversion, and experiences of stigma. J Subst Abuse Treat. 2016;70:81–86. doi:10.1016/j.jsat.2016.08.002. PMID:27692193.
  • Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O'Grady KE, Jaffe JH. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89–95. doi:10.1016/j.jsat.2015.05.005. PMID:25986647.
  • Corrigan PW, Rao D. On the self-stigma of mental illness: stages, disclosure, and strategies for change. The Canadian Journal of Psychiatry. 2012;57(8):464–469. doi:10.1177/070674371205700804. PMID:22854028.
  • Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK general practice research database. BMJ. 2010;341. doi:10.1136/bmj.c5475. PMID:20978062.
  • Maryland Department of Health and Mental Hygiene. Drug- and Alcohol-Related Intoxication Deaths in Maryland, 2014. https://bha.health.maryland.gov/OVERDOSE_PREVENTION/Documents/2015%20Annual%20Report_final.pdf. Published June 2016. Access November 28, 2016.
  • Daniels AM, Salisbury-Afshar E, Hoffberg A, Agus D, Fingerhood MI. A novel community-based buprenorphine program: client description and initial outcomes. J Addict Med. 2014;8(1):40–46. doi:10.1097/ADM.0000000000000004. PMID:24394496.
  • Behavioral Health Leadership Institute. Project connections buprenorphine program: program and Client summary 2010–2016. http://mail.bhli.org/pdf/BHLIBupeProgramReportSept2016.pdf. Published September 2016. Accessed January 28, 2017.
  • Maintenance and recovery services. Mars methadone web site. http://marsmethadone.com/about-us. Updated 2016. Accessed November 6, 2016.
  • SMART recovery—self-management for addiction recovery. SMART recovery web site. http://www.smartrecovery.org/. Updated 2016. Accessed November 6, 2016.
  • Gilman SM, Galanter M, Dermatis H. Methadone anonymous: a 12-step program for methadone maintained heroin addicts. Substance Abuse. 2001;22(4):247–256. doi:10.1080/08897070109511466. PMID:12466684.
  • Ginter W. Methadone anonymous and mutual support for medication-assisted recovery. Journal of Groups in Addiction & Recovery. 2012;7(2–4):189–201. doi:10.1080/1556035X.2012.705699.
  • Hsieh H, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288. doi:10.1177/1049732305276687. PMID:16204405.
  • White WL, Campbell MD, Shea C, Hoffman HA, Crissman B, DuPont RL. Coparticipation in 12-step mutual aid groups and methadone maintenance treatment: a survey of 322 patients. Journal of Groups in Addiction & Recovery. 2013;8(4):294–308. doi:10.1080/1556035X.2013.836872.
  • Wakeman SE. Language and addiction: choosing words wisely. Am J Public Health. 2013;103(4):e1–e2. doi:10.2105/AJPH.2012.301191. PMID:23409913.
  • Dickey B, Normand ST, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatric Services. 2002;53(7):861–7. doi:10.1176/appi.ps.53.7.861.
  • De Hert M, Vancampfort D, Detraux J. Somatic problems and dual disorder patients. In: Dom G, Moggi F, eds. Co-occurring Addictive and Psychiatric Disorders. Berlin, Germany: Springer; 2015:349–361.
  • Saloner B, Sharfstein J. A stronger treatment system for opioid use disorders. JAMA. 2016;315(20):2165–2166. doi:10.1001/jama.2016.3674. PMID:27218625.
  • US Department of Health and Human Services (HHS), Office of the Surgeon General. Facing addiction in America: the surgeon general's report on alcohol, drugs, and health. https://addiction.surgeongeneral.gov/surgeon-generals-report.pdf. Published 2016. Accessed November 19, 2016.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.